Curetis To Attend Key Conferences in the Second Quarter of 2019
Amsterdam, the Netherlands, and Holzgerlingen, Germany, April 1, 2019, 03:00 pm CET - Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that the Company will be attending several key conferences in the second quarter of 2019.
April 2019H.C. Wainwright Global Life Sciences Conference, April 8-9, 2019 – London, United Kingdom – company presentation and one-on-one investor meetings.Northeast Association of Clinical Microbiology and Infectious Disease, April 8-9, 2019 – Portsmouth, NH, USA, Sheraton Portsmouth Harborside Hotel.
DBT German Biotech Days, April 9-10, 2019, Wuerzburg, Germany.
29th ECCMID 2019, April 13-16, 2019 – Amsterdam, the Netherlands, RAI Amsterdam, Booth #1.65.
ASM Clinical Virology Symposium, May 5-8, 2019 – Savannah, GA, USA, Savannah International Trade and Convention Center, Booth #426.
22nd Annual MAD-ID Meeting, May 8-11, 2019 – Orlando, FL, USA, Rosen Centre Hotel.
ASM Microbe 2019, June 20-24, 2019 – San Francisco, CA USA, Moscone Center, Booth #1236.
Curetis N.V.’s (Euronext: CURE) goal is to become a leading provider of innovative solutions for molecular microbiology diagnostics designed to address the global challenge of detecting severe infectious diseases and identifying antibiotic resistances in hospitalized patients.
Curetis’ Unyvero System is a versatile, fast and highly automated molecular diagnostic platform for easy-to-use, cartridge-based solutions for the comprehensive and rapid detection of pathogens and antimicrobial resistance markers in a range of severe infectious disease indications. Results are available within hours, a process that can take days or even weeks if performed with standard diagnostic procedures, thereby facilitating improved patient outcomes, stringent antibiotic stewardship and health-economic benefits. Unyvero in vitro diagnostic (IVD) products are marketed in Europe, the Middle East, Asia and the U.S.
Curetis’ wholly owned subsidiary Ares Genetics GmbH is developing next-generation solutions for infectious disease diagnostics and therapeutics. The ARES Technology Platform combines the presumably most comprehensive database worldwide on the genetics of antimicrobial resistances, ARESdb, with advanced bioinformatics and artificial intelligence.
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.
The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This press release includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should”, and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis’ actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
Curetis GmbHMax-Eyth-Str. 4271088 Holzgerlingen, GermanyTel. +49 7031 49195-10 firstname.lastname@example.org or email@example.com
Curetis International Media & Investor InquiriesakampionDr. Ludger Wess / Ines-Regina Buth Managing Partnersinfo(@)akampion.comTel. +49 40 88 16 59 64Tel. +49 30 23 63 27 68